Sun Pharma's FEXUCLUE: The Game-Changing Treatment for Erosive Esophagitis

Sun Pharmaceutical Industries Limited has achieved a major milestone in the history of Indian pharma by introducing FEXUCLUE (Fexuprazan) 40 mg tablets, a new potassium-competitive acid blocker (PCAB), for the management of erosive esophagitis. This launch is a part of Sun Pharma's strategic collaboration with Daewoong Pharmaceutical Co. Ltd., Korea, which has provided exclusive rights to produce and market FEXUCLUE in India.

 

Key Highlights:

This launch reinforces Sun Pharma's intent to bring to market innovative, patient-focused treatments that improve patients' quality of life in India.

 

Source: Business Upturn, Medical Dialogues, India Pharma Outlook